RxDoctor Payments Data

Syed Qadri, MD

Nephrology · Altamonte Springs, FLNPI 1235497256

Payments from drug & device makers

$1,694in general payments, 2019–2025

Across 55 payments — averaging $30.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$571
  • Amgen$547
  • Mallinckrodt Hospital Products Inc.$129
  • Baxter Healthcare$118
  • Otsuka America Pharmaceutical, Inc.$99
  • Calliditas Therapeutics US Inc.$97
  • plus $132 from 5 others

What the payments were for

  • Food & beverage$1,59494%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,694 in reported general payments places this provider in the 45th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$248,796
Medicare patients
527
Services billed
1,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin163$198,221
FarxigaDapagliflozin Propanediol132$146,699
KerendiaFinerenone86$111,041
VelphoroSucroferric Oxyhydroxide17$56,484
OzempicSemaglutide41$39,765
LokelmaSodium Zirconium Cyclosilicate30$33,272
ProsolParenteral Amino Acid 20% No.165$15,578
Sevelamer Carbonate53$14,642
RayaldeeCalcifediol11$12,640
EntrestoSacubitril/Valsartan13$12,001
Cinacalcet Hcl21$11,958
Potassium Citrate ErPotassium Citrate32$5,149
Olmesartan Medoxomil179$3,940
Bumetanide105$3,240
Losartan Potassium232$2,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$14$179,971162 claims
BayerKerendia$48$111,04186 claims
Fresenius USA Marketing, Inc.Velphoro$38$56,48417 claims
Novo NordiskOzempic$15$39,76541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 756 nephrology providers in Florida.

Other nephrology in Altamonte Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →